HC Wainwright Forecasts Weaker Earnings for Pharming Group

Pharming Group (NASDAQ:PHAR) – Analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for shares of Pharming Group in a research note issued on Thursday, October 24th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $2.20 for the year, down from their previous forecast of $2.42. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Separately, Oppenheimer reduced their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday.

Pharming Group Price Performance

Pharming Group stock opened at $8.55 on Monday. Pharming Group has a 12-month low of $6.65 and a 12-month high of $13.20. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $8.08 and a 200-day moving average price of $8.50. The firm has a market capitalization of $579.95 million, a PE ratio of -32.88 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The company had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same quarter in the prior year, the business earned $0.02 earnings per share.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.